Evidence of comparative efficacy should have a formal role in European drug approvals

Sorenson, Corinna, Naci, Huseyin, Cylus, Jonathan and Mossialos, Elias (2011) Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal, 343 (7822). d4849-d4849. ISSN 0959-8138

Preview

PDF Download (299Kb) | Preview

• LSE expert's profile
• LSE expert's profile
• LSE expert's profile

• Published item via DOI

Abstract

Despite methodological concerns, comparative efficacy evidence should be required at the time of drug approval, says Corinna Sorenson and colleagues, to allow patients, clinicians, and other healthcare decision makers to determine whether a new drug is superior, equivalent, or inferior to its existing alternatives.

Item Type:	Article
Official URL:	http://www.bmj.com/
Additional Information:	© 2011 BMJ Publishing Group
Library of Congress subject classification:	R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology
Sets:	Departments > Social Policy Research centres and groups > LSE Health Research centres and groups > ALPHA (Ageing, Lifecourse and Population Health Analysis)
Date Deposited:	09 Sep 2011 12:50
URL:	http://eprints.lse.ac.uk/38191/

Actions (login required)

Record administration - authorised staff only